Worth discussing, worth knowing. Etoricoxib Review article
Article Sidebar
Published:
Dec 31, 2022
Keywords:
etoricoxib, NSAIDs, diseases of the musculoskeletal system
Main Article Content
Abstract
The effectiveness and side effects of etoricoxib are discussed in this paper. Etoricoxib is a strong nonsteroidal anti-inflammatory drug used in diseases of the musculoskeletal system. The effectiveness of the drug is comparable to that of diclofenac. Treatment tolerance is good. It causes fewer gastrointestinal and hepatic side effects than diclofenac, and patients discontinue the drug less frequently. Cardiovascular complications occur with a similar frequency as with diclofenac. Etoricoxib is more likely to increase blood pressure.
Article Details
How to Cite
Rell-Bakalarska, M., & Rell, K. (2022). Worth discussing, worth knowing. Etoricoxib. Medycyna Faktow (J EBM), 15(4(57), 414-417. https://doi.org/10.24292/01.MF.0422.7
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390: e21-33.
2. Gottesdiener K, Schnitzer T, Fisher C et al. Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002; 41(9): 1052-61.
3. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
4. Baraf HS, Fuentealba C, Greenwald M et al. Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial. J Reumatol. 2007; 34: 408-20.
5. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008; 67(3): 315-22.
6. Matsumoto AK, Melian A, Mandel DR et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29(8): 1623-30.
7. Bickham K, Kivitz AJ, Mehta A. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
9. Gratacós J, Moreno M-LM, Font P et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016; 34(1): 94-9.
10. Schumacher Jr HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352): 1488-92.
11. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5): 715-22.
12. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086.
13. Krum H, Swergold G, Gammaitoni A et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012; 30(6): 342-50.
14. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69: 365-71.
15. Yaxley J, Litfin T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail. 2016; 38(9): 1328-34.
2. Gottesdiener K, Schnitzer T, Fisher C et al. Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002; 41(9): 1052-61.
3. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
4. Baraf HS, Fuentealba C, Greenwald M et al. Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial. J Reumatol. 2007; 34: 408-20.
5. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008; 67(3): 315-22.
6. Matsumoto AK, Melian A, Mandel DR et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29(8): 1623-30.
7. Bickham K, Kivitz AJ, Mehta A. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
9. Gratacós J, Moreno M-LM, Font P et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016; 34(1): 94-9.
10. Schumacher Jr HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352): 1488-92.
11. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5): 715-22.
12. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086.
13. Krum H, Swergold G, Gammaitoni A et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012; 30(6): 342-50.
14. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69: 365-71.
15. Yaxley J, Litfin T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail. 2016; 38(9): 1328-34.